Firefly Neuroscience Grants Inducement Shares to Executive Chairman, Highlighting AI-Driven Brain Health Solutions

Firefly Neuroscience Announces Inducement Grant

Firefly Neuroscience, Inc. (NASDAQ: AIFF), an Artificial Intelligence (AI) company specializing in brain health solutions, has announced a significant inducement grant to its Executive Chairman, David Johnson. The company's Board of Directors has granted 557,885 restricted shares to Mr. Johnson as part of his employment agreement 1

1

2

Grant Details and Vesting Schedule

The shares were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms of the employment agreement and Firefly's 2024 Long-Term Incentive Plan. The vesting schedule for these shares is as follows:

• 50% of the shares will vest on the sixth-month anniversary of the grant date
• The remaining 50% will vest on the twelfth-month anniversary

This vesting is contingent upon Mr. Johnson not incurring a termination of service prior to the applicable vesting dates 1

1

2

Firefly's AI-Driven Brain Health Solutions

Firefly Neuroscience is at the forefront of developing innovative AI solutions for improving brain health outcomes. The company's flagship technology, Brain Network Analytics (BNA™), has received FDA-510(k) clearance and is poised to revolutionize diagnostic and treatment monitoring methods for various neurological and mental disorders 1

1

Key Features of BNA™ Technology:

1. Utilizes AI and machine learning
2. Based on a proprietary database of over 17,000 patient EEGs
3. Covers twelve disorders and clinically normal patients
4. Provides comprehensive insights into brain function

Applications and Target Markets

Firefly is now launching BNA™ commercially, targeting two primary markets:

1. Pharmaceutical companies engaged in drug research and clinical trials
2. Medical practitioners for clinical use in diagnosing and treating conditions such as depression, dementia, anxiety disorders, concussions, and ADHD 1

   1

   2

   2

Related Stories

Firefly Neuroscience Secures $12.4 Million Financing to Advance AI-Powered Brain Health Technology

Firefly Neuroscience's AI-Powered EEG Analytics Show Promise in Drug Development and Neuropsychiatric Care

Firefly Neuroscience Appoints Greg Lipschitz as Executive Chairman, Strengthening AI-Driven Brain Health Solutions

Firefly Neuroscience to Showcase AI-Powered Brain Health Solutions at October Investor Conferences

Company Background and Achievements

Over the past 15 years, Firefly has made significant strides in the field of brain health:

• Built a comprehensive database of brain wave tests
• Secured patent protection for its technology
• Achieved FDA clearance for BNA™

The company's innovative approach combines AI-driven analysis with high-definition longitudinal electroencephalograms (EEGs) to enhance clinicians' ability to accurately diagnose mental and cognitive disorders and optimize treatment outcomes 1

1

2

Forward-Looking Statements and Risk Factors

While Firefly Neuroscience expresses optimism about its future prospects, the company has also issued cautionary statements regarding forward-looking projections. These include potential risks related to:

• Development and commercialization of BNA™ technology
• Realizing anticipated benefits from the recent merger with WaveDancer, Inc.
• Accurately estimating operating expenses and costs
• Protecting intellectual property rights
• Competitive responses and market challenges 1

  1

  2

  2

As Firefly Neuroscience continues to advance its AI-driven brain health solutions, the company remains committed to improving outcomes for patients with neurological and mental disorders while navigating the complex landscape of medical technology development and commercialization.